CR9623A - Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos - Google Patents

Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos

Info

Publication number
CR9623A
CR9623A CR9623A CR9623A CR9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A
Authority
CR
Costa Rica
Prior art keywords
nogo
humanized antibodies
pharmaceutical uses
specific humanized
antibodies
Prior art date
Application number
CR9623A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Farhana Hussain
Alan Peter Lewis
Ruth Mcadam
Rabinder Prinjha
Paul Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR9623A publication Critical patent/CR9623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a anticuerpos para NOGO, a las formulaciones farmaceuticas que los contienen y al uso de tales anticuerpos en el tratamiento y/o profilaxis de enfermedades/trastornos neurologicos.
CR9623A 2005-07-05 2007-12-20 Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos CR9623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins

Publications (1)

Publication Number Publication Date
CR9623A true CR9623A (es) 2008-04-10

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9623A CR9623A (es) 2005-07-05 2007-12-20 Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos

Country Status (22)

Country Link
EP (1) EP1899377B1 (es)
JP (1) JP2009500363A (es)
KR (1) KR20080030960A (es)
AU (1) AU2006265276B2 (es)
BR (1) BRPI0612734A2 (es)
CA (1) CA2614076A1 (es)
CR (1) CR9623A (es)
CY (1) CY1113310T1 (es)
DK (1) DK1899377T3 (es)
EA (1) EA014291B1 (es)
ES (1) ES2391902T3 (es)
HK (1) HK1115598A1 (es)
HR (1) HRP20120851T1 (es)
IL (1) IL188282A (es)
MA (1) MA29625B1 (es)
NO (1) NO20076663L (es)
NZ (1) NZ564567A (es)
PL (1) PL1899377T3 (es)
PT (1) PT1899377E (es)
SG (1) SG162829A1 (es)
SI (1) SI1899377T1 (es)
WO (1) WO2007003421A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
RU2513697C2 (ru) * 2007-11-02 2014-04-20 Новартис Аг Улучшенные молекулы, связывающиеся с nogo-а и их фармацевтическое применение
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
KR20210118085A (ko) 2018-12-21 2021-09-29 키맵 리미티드 공통 경쇄를 갖는 ＦＩＸａｘＦＸ 이중특이적 항체
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
BRPI0417959A (pt) * 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável

Also Published As

Publication number Publication date
PL1899377T3 (pl) 2013-01-31
SI1899377T1 (sl) 2012-12-31
ES2391902T3 (es) 2012-11-30
EA200702634A1 (ru) 2008-06-30
NZ564567A (en) 2010-09-30
NO20076663L (no) 2008-02-27
BRPI0612734A2 (pt) 2010-11-30
PT1899377E (pt) 2012-11-20
CA2614076A1 (en) 2007-01-11
JP2009500363A (ja) 2009-01-08
DK1899377T3 (da) 2012-11-12
SG162829A1 (en) 2010-07-29
AU2006265276A1 (en) 2007-01-11
EP1899377A2 (en) 2008-03-19
MA29625B1 (fr) 2008-07-01
WO2007003421A3 (en) 2007-04-12
HK1115598A1 (en) 2008-12-05
EP1899377B1 (en) 2012-08-22
AU2006265276B2 (en) 2011-10-13
KR20080030960A (ko) 2008-04-07
IL188282A0 (en) 2008-04-13
IL188282A (en) 2011-04-28
EA014291B1 (ru) 2010-10-29
WO2007003421A2 (en) 2007-01-11
CY1113310T1 (el) 2016-04-13
HRP20120851T1 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
AR048912A1 (es) Inmunoglobulinas anti-nogo
AR057239A1 (es) Inmunoglobulinas
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
PA8632801A1 (es) Derivados de tetrahidronaftiridina
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
NI200700010A (es) Moduladores de los receptores de alfa 7 acetilcolina nicotinica y sus usos terapéuticos
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CR9623A (es) Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
DOP2010000069A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias

Legal Events

Date Code Title Description
FC Refusal